
SAFC

Zinc Finger Nucleases for Precise Editing of the CHO Cell Genome

- Bi-allelic knockouts are routine; multiple alleles are modified in a single step
- Genomic modifications are precise, permanent and heritable
- Six weeks from DNA to phenotype of bi-allelic knockouts
- Technical support from team of experts

ZFN-mediated Genome Editing Process



Applications to CHO Cell Engineering

- Improve cell culture performance: titer, growth, longevity
- Enhance product quality and efficacy by modification of glycosylation
- Remove interfering host cell proteins: endogenous CHO cell molecules that co-purify or otherwise interfere with product yield
- Introduce metabolic selection markers: bi-allelic knockouts of GS or DHFR

ZFN Catalog Products

Product Name	Cat. No.
CompoZr® Knockout ZFN Kit- CHO GS glutamine synthetase	ZFNGS-1KT*
CompoZr® Knockout ZFN Kit- CHO DHFR dihydrofolate reductase	ZFNDHFR-50UG*

* All products are delivered as plasmid DNA

Cell Design Studio (CDS)

Service	Lead Time	Cost	Cat. No.
Custom ZFN reagents	8-10 weeks	Upon Request	SAFCZFN-1KT
CDS*	16-18 weeks*	Varies*	N/A

- * Cell Design Studio can perform ZFN knockout in customer cell line or SAFC cell line in our labs. Lead times and cost vary depending on project complexity.
- ¹ Investigational new drug (application)



SAFC® CompoZr® ZFNs



CHOZN® ZFN-modified CHO Cell Lines

SAFC has created a series of zinc finger nuclease (ZFN) modified CHO cell lines with characteristics that are desirable in a platform cell line. These cell lines have the ability to reliably produce clones that exhibit favorable characteristics, including:

- High growth and productivity both Qp and volumetric
- Suspension growth in chemically-defined media
- · Responsiveness to feeds
- Scalability in bioreactors
- Complete traceability and safety testing

CHOZN ZFN-modified CHO Cell Lines

Name		Cat. No.	Format
CHOZN DHFR-/-	CHO Cell Line	CHODHFR-1VL	1 mL frozen vial containing >7.5e6 cells/mL
CHOZN GS-/- CH	HO Cell Line	CHOGS-1VL	1 mL frozen vial containing >7.5e6 cells/mL

Features

CHOZN GS

- First ever commercially available GS knockout CHO cell line
- CHOZN GS line developed by targeted mutagenesis with ZFNs in a suspension adapted ECACC CHO-K1 parental
- Strong metabolic selection, which means fewer clones need to be screened = decreased cell line development resources
- No MSX required for selection/amplification
- cGMP manufactured/banked
- No IP or associated royalties

CHOZN DHFR

- CHOZN DHFR line developed by targeted mutagenesis with ZFNs in a suspension adapted ECACC CHO-K1 parental
- DHFR selection is industry-accepted method
- No IP or associated royalties

Contact Us

Trissa Borgschulte, Ph.D.

Principal Scientist-Cell Line Engineering

+1-314-289-8496 x1916

Trissa.Borgschulte@sial.com

Kevin Kayser, Ph.D.

Associate Director, Cell Sciences & Development +1-314-286-7896 (direct)

+1-314-494-0323 (mobile)

Kevin.Kayser@sial.com

Becky Schuchhardt

CompoZr-ZFN Product Manager

+1-913-227-6794 (direct)

+1-913-207-8882 (mobile)

Rebecca.Schuchhardt@sial.com

Kevin Gutshall

Licensing and Business Development +1-314-306-2648

Kevin.Gutshall@sial.com

For more information, call 1-800-255-6032 or email at technicalservices@sial.com.



NOQ 80619-509909 1043 ©2013 Sigma-Aldrich Co. LLC. All rights reserved. SAFC and SIGMA-ALDRICH are trademarks of Sigma-Aldrich Co. LLC, registered in the US and other countries. CompoZr and CHOZN are registered trademarks belonging to Sigma-Aldrich Co. LLC. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply, Please see product information on the SAFC website at www.safcglobal.com and/or on the reverse side of the invoice or packing slip.